Related Experiment Video

Updated: Oct 31, 2025

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma
12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

19.6K

Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?

Aini Hyytiäinen1,2, Wafa Wahbi1,2, Otto Väyrynen1

  • 1Department of Oral and Maxillofacial Diseases, Clinicum, University of Helsinki, Helsinki, Finland.

Frontiers in Oncology
|July 1, 2021
PubMed
Abstract

Insights

Angiogenesis inhibitors show limited benefit and significant toxicity in head and neck squamous cell carcinoma (HNSCC) treatment. Further research into combination therapies is warranted for HNSCC patients.

Area of Science:

  • Oncology
  • Cancer Research
  • Clinical Trials

Background:

  • Head and neck squamous cell carcinoma (HNSCC) has poor survival rates despite advances in cancer treatment.
  • Angiogenesis is vital for tumor growth and progression, leading to the development of angiogenesis inhibitors.
  • This systematic review evaluates clinical trial data on angiogenesis inhibitors for HNSCC.

Approach:

  • A literature search was conducted across multiple databases (Ovid MEDLINE, Cochrane Library, Scopus, ClinicalTrials.gov).
  • The review focused on three categories of angiogenesis inhibitors: bevacizumab, tyrosine kinase inhibitors, and endostatin.
  • 38 clinical trials involving 1670 patients were analyzed.

Key Points:

  • Bevacizumab was the most studied agent but associated with high toxicity.
  • Endostatin and lenvatinib demonstrated promising anticancer effects and good tolerability.
  • Most trials were Phase I or II, with one Phase III trial on bevacizumab.

Conclusions:

  • Angiogenesis inhibitors generally did not demonstrate significant benefit in HNSCC treatment.
  • Considerable toxicity was observed with angiogenesis inhibitors.
  • Encouraging results suggest further investigation, especially in combination therapies, is warranted for HNSCC.
Keywords:
anti-angiogenesisbevacizumabendostatinhead and neck cancertherapy

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.8K
A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma08:59

A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma

Published on: January 5, 2017

10.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.0K
Veins of Head and Neck01:19

Veins of Head and Neck

The blood drainage from the head and neck is primarily managed by three pairs of veins: the external jugular, internal jugular, and vertebral veins. The external jugular veins drain superficial scalp and face structures, passing over the sternocleidomastoid muscles to empty into the subclavian veins.
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
3.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
785